Zentalis Pharmaceuticals' (ZNTL) "Outperform" Rating Reiterated at Leerink Partners

Key Points

• Leerink Partners reiterated its “Outperform” rating on Zentalis Pharmaceuticals and doubled its price target to $8 from $4, implying 217.46% potential upside from the prior close.
• Analyst sentiment is broadly positive, with six Buy ratings, three Holds and one Sell; MarketBeat reports a consensus “Moderate Buy” rating and a $7.50 average target price.
• Zentalis shares opened at $2.52, while the company reported a quarterly loss of $0.59 per share, missing the $0.49 consensus estimate. Major shareholder Group Walters also increased its stake by 4.335 million shares.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report)'s stock had its "outperform" rating reiterated by analysts at Leerink Partners in a report released on Monday, Benzinga reports. They currently have a $8.00 price target on the stock, up from their prior price target of $4.00. Leerink Partners' price target would suggest a potential upside of 217.46% from the stock's previous close.

Several other equities research analysts have also commented on the stock. Rodman & Renshaw assumed coverage on shares of Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They set a "buy" rating and a $11.00 price objective on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Zentalis Pharmaceuticals in a report on Friday. William Blair began coverage on Zentalis Pharmaceuticals in a research report on Wednesday, September 16th. They issued an "outperform" rating on the stock. Wall Street Zen downgraded Zentalis Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 8th. Finally, Wells Fargo & Company began coverage on Zentalis Pharmaceuticals in a research report on Wednesday, September 30th. They set an "equal weight" rating and a $5.00 price objective for the company. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $7.50.

Zentalis Pharmaceuticals Stock Performance

ZNTL opened at $2.52 on Monday. The company has a market cap of $180.61 million, a price-to-earnings ratio of -1.29 and a beta of 1.93. The stock has a fifty day simple moving average of $3.75 and a two-hundred day simple moving average of $3.86. Zentalis Pharmaceuticals has a 12-month low of $1.21 and a 12-month high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.10). On average, analysts predict that Zentalis Pharmaceuticals will post -2.11 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Group Walters acquired 4,335,000 shares of the firm's stock in a transaction dated Friday, August 14th. The shares were purchased at an average price of $3.50 per share, with a total value of $15,172,500.00. Following the completion of the purchase, the insider directly owned 17,844,973 shares of the company's stock, valued at $62,457,405.50. This represents a 32.09% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. 5AM Venture Management LLC bought a new position in shares of Zentalis Pharmaceuticals in the second quarter worth approximately $19,147,378. BlackRock Inc. bought a new stake in Zentalis Pharmaceuticals during the second quarter valued at about $18,205,000. Bank of America Corp DE purchased a new position in shares of Zentalis Pharmaceuticals in the second quarter valued at about $5,406,000. Primecap Management Co. CA bought a new position in shares of Zentalis Pharmaceuticals in the second quarter worth about $4,643,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Zentalis Pharmaceuticals during the 2nd quarter valued at approximately $3,676,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc NASDAQ: ZNTL is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company's research programs are designed to target biological pathways involved in tumor growth, survival and resistance to existing therapies.

Zentalis' lead investigational product is azenosertib, also known as ZN-c3, an oral WEE1 inhibitor being evaluated in clinical trials for several advanced cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.